Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
Trial Snapshot
- Phase
- Phase 4
- Status
- Terminated
- Sponsor
- University of Zurich
- Primary Endpoint
- change in endothelial function
Study Overview
Brief Summary
The randomized, double-blind, placebo-controlled study aim to evaluate the effect of 1-month therapy with folic acid (5 mg/day) on endothelial function and baroreceptor function in patients with heart failure.
Endothelial function will be studied non-invasively with flow-mediated dilation while for eveluating baroreceptor function sympathetic nervous system activity will be measured directly with microneurography in baseline condition and during infusion of sodium-nitroprusside.
Detailed Description
Endothelial and baroreceptor function are impaired in patients with heart failure.
Impaired baroreflex control of the heart and peripheral circulation and endothelial dysfunction are thought to play an important pathophysiological role in chronic heart failure and confers a poor prognosis.
In patients with essential hypertension we demonstrated an improvement in baroreceptor function after treatment with folic acid.
Therefore, the aim of the present randomized, double-blind, placebo-controlled study was to evaluate endothelial function and baroreceptor function in patients with heart failure before and after 1-month therapy with folic acid (5 mg) or placebo.
Endothelial function will be assessed with novel high-resolution ultrasound devices, which allows to investigate endothelial function in vivo. This method makes use of the property of the endothelium to release nitric oxide in response to shear stress and increased flow as previously described. Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent glycerol trinitrate (GTN) (0.4 mg sublingual, Nitrolingual Spray, Pohl-Boskamp, Germany)-induced vasodilation of the brachial artery will be assessed by a high-resolution ultrasound vessel wall tracking device with a 10 MHz linear array transducer . FMD of the brachial artery is induced by release of a wrist cuff inflated 50 mmHg above systolic pressure for 5 minutes. After sublingual GTN application, used as endothelium-independent stimulus, the diameter will be recorded every 30 seconds for 6 minutes.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Heart failure (min. NYHA ll, LVEF <50%)
- •Not smokers
- •Written informed consent
Exclusion Criteria
- •Unstable heart failure
- •Unstabile Angina Pectoris
- •Endocrinologic disease such as Diabetes mellitus, Hypo- und Hyperthyroidism
- •Alcohol abuse
- •Epilepsia
- •Treatment with folic acid antaponists Trimethoprim, Pyrimethamin, Methotrexat..
- •Participation to one other clinical Study within 1 Month
Outcomes
Primary Outcomes
change in endothelial function
Time Frame: 1 month
change in baroreceptor function
Time Frame: 1 month
Secondary Outcomes
No secondary outcomes reported